See what you missed at USCAP 2024: Innovation in digital pathology workflows for IHC & FISH and advancing HER2 scoring accuracy.

Hereditary Cancer

Genetic testing can help high-risk patients learn more about their chances of developing certain cancers later in life. Genetically inherited cancers account for approximately 10% for some types of cancers, as some inherited pathogenic variants in certain genes may increase an individual’s risk of developing such cancers during their lifetime. For example, individuals carrying pathogenic variants in BRCA1 and BRCA2 genes are at significantly increased risk of developing breast, ovarian, prostate, pancreatic and other cancers with varying age of onset. This is why early detection through hereditary cancer testing can be extremely beneficial for patients who need answers to make important life decisions.

A cancer risk assessment can result in highly targeted treatment and therapy options, clarity on the progression of cancers, surgical intervention, or even the opportunity to participate in ongoing clinical trials for hereditary cancers.

Cancer genetic screening can be performed simply through a peripheral blood and the expertise of our molecular pathologists. CorePath offers next generation sequencing (NGS)-based genetic testing to identify pathogenic single nucleotide variants (SNVs) and copy number variants (CNVs) in cancer predisposition genes associated with breast cancer, ovarian cancer, colorectal cancer, Lynch syndrome, and neuroendocrine disorders. CorePath provides various options for analyzing clinically significant genes early, as well as genetic counseling services to patients before and after genetic testing for complete peace of mind.

See our hereditary cancer resources below for more information.